Gilde Healthcare raises €600 million to invest in healthcare innovation - Gilde Healthcare

Gilde Healthcare raises €600 million to invest in healthcare innovation

April 19, 2023
Utrecht (the Netherlands)
  • A balanced mix of international investors commits €600 million to Gilde Healthcare Venture&Growth VI, a transatlantic investment fund
  • Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by its recently appointed Impact Council
  • In three years’ time, Gilde Healthcare raised over €1.5 billion across three funds

Gilde Healthcare today announces a new investment fund with €600 million in commitments: Gilde Healthcare Venture&Growth VI. The new fund focuses on fast growing companies developing solutions for better care at lower cost. Gilde Healthcare invests in companies in Europe and North America active in digital healthcare, medical technology (MedTech) and therapeutics.

The fund is backed by a balanced mix of international investors, including corporates, banks, pension funds, insurers, fund-of-funds, sovereign wealth funds, endowments, family offices, entrepreneurs and the Gilde team.

Pieter van der Meer, Managing Partner at Gilde Healthcare: “We are pleased with the strong interest from investors who support our mission. Innovations that improve the quality of care but also keep it affordable are essential to ensure access to healthcare. Our broad strategy, covering digital health, MedTech and therapeutics, results in a holistic approach allowing us to select the most optimal and cost effective solution for the individual patient. With a team of sector experts, we help companies to further scale medical innovations and to make them accessible globally.”

The healthcare expenditure in the Western World continues to grow, already exceeding 20% of GDP in the United States. Gilde Healthcare’s mission to invest in better care at lower cost, is supported by the recently established Impact Council, chaired by the former executive director of the European Medicines Agency (EMA).

The new fund will invest €10-60 million per new portfolio company. Together with the last Venture&Growth fund (closed in 2020) and Gilde Healthcare Private Equity IV (closed in 2022), Gilde Healthcare has raised €1.5 billion in capital over the last three years.

Media contact:
Ruben Cardol (media contact)
email: ruben.cardol@cffcommunications.nl
phone: +31 (0)6 55 358 427

Pieter van der Meer (Managing Partner)
email: vandermeer@gildehealthcare.com
phone: +31 30 219 2565

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €2.5 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
May 21, 2024

Gilde Healthcare co-leads $100M equity financing in Karius

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and...
May 2, 2024

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024